• Product nameAnti-CACNB4 antibody
    See all CACNB4 primary antibodies
  • Description
    Goat polyclonal to CACNB4
  • SpecificityThis antibody is expected to recognise all reported protein isoforms of human CACNB4.
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat, Pig
  • Immunogen

    Synthetic peptide:


    , corresponding to C terminal amino acids 508-520 of Human CACNB4

  • Positive control
    • Lysates prepared from human bone marrow. Lysates prepared from transfected HEK293 transiently expressing CACNB4.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 0.5% BSA, Tris buffered saline. pH 7.3
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesThis antibody has been purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab26060 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.3 - 1 µg/ml. Detects a band of approximately 60 kDa (predicted molecular weight: 59 kDa).


  • FunctionThe beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
  • Tissue specificityExpressed predominantly in the cerebellum and kidney.
  • Involvement in diseaseGenetic variations in CACNB4 are the cause of susceptibility to idiopathic generalized epilepsy type 9 (IGE9) [MIM:607682]. IGE9 is characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.
    Genetic variations in CACNB4 are the cause of susceptibility to juvenile myoclonic epilepsy type 6 (EJM6) [MIM:607682]. EJM6 is a subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.
  • Sequence similaritiesBelongs to the calcium channel beta subunit family.
    Contains 1 SH3 domain.
  • Information by UniProt
  • Database links
  • Alternative names
    • CAB4 antibody
    • CACB4_HUMAN antibody
    • Cacnb4 antibody
    • CACNLB4 antibody
    • Calcium channel voltage dependent beta 4 subunit antibody
    • Calcium channel voltage dependent subunit beta 4 antibody
    • Calcium channel voltage-dependent subunit beta 4 antibody
    • Dihydropyridine sensitive L type calcium channel beta 4 subunit antibody
    • EA5 antibody
    • EIG9 antibody
    • EJM antibody
    • EJM4 antibody
    • EJM6 antibody
    • Voltage-dependent L-type calcium channel subunit beta-4 antibody
    see all

Anti-CACNB4 antibody images

References for Anti-CACNB4 antibody (ab26060)

This product has been referenced in:
  • Mehmood T  et al. Transcriptome profile reveals AMPA receptor dysfunction in the hippocampus of the Rsk2-knockout mice, an animal model of Coffin-Lowry syndrome. Hum Genet 129:255-69 (2011). WB ; Mouse . Read more (PubMed: 21116650) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab26060.
Please use the links above to contact us or submit feedback about this product.